| abstract |
The subject matter described herein is a composition comprising a MEK inhibitor or a pharmaceutically acceptable salt thereof, and a multi-kinase inhibitor targeting a PDGFR [alpha], S6 and STAT3, or a pharmaceutically acceptable salt thereof; And its use in the treatment of pancreatic cancer. In another aspect, disclosed herein is a method of treating a pancreatic cancer by administering a MEK inhibitor, or a pharmaceutically acceptable salt thereof, and a multi-kinase inhibitor, or a pharmaceutically acceptable salt thereof. In another embodiment, a combination of cobimetinib or a pharmaceutically acceptable salt thereof and a combination of fornatibem or a pharmaceutically acceptable salt thereof is administered to the composition, or the combination is administered separately to treat pancreatic cancer. |